135 related articles for article (PubMed ID: 38412399)
21. Effect of a Novel Soaking Solution Used in Patients With Hand-Foot Syndrome as a Result of Capecitabine Treatment: A Randomized and Self-Controlled Trial.
Xie Y; Wang Q; Hu T; Chen R; Wang J; Chang H; Peng X; Cheng J
Clin Breast Cancer; 2022 Jul; 22(5):e685-e690. PubMed ID: 35354530
[TBL] [Abstract][Full Text] [Related]
22. Hand-foot syndrome in cancer patients on capecitabine: examining prevalence, impacts, and associated risk factors at a cancer centre in Malaysia.
King TL; Voon PJ; Yuen KH; Mohamed Noor DA
Support Care Cancer; 2024 May; 32(6):345. PubMed ID: 38743316
[TBL] [Abstract][Full Text] [Related]
23. Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer.
Lin S; Yue J; Guan X; Yuan P; Wang J; Luo Y; Fan Y; Cai R; Li Q; Chen S; Zhang P; Li Q; Ma F; Xu B
Cancer Commun (Lond); 2019 Oct; 39(1):57. PubMed ID: 31601265
[TBL] [Abstract][Full Text] [Related]
24. A pilot randomized double-blind, placebo-controlled study on the effects of the topical application of pyridoxine on palmar-plantar erythrodysesthesia (PPE) induced by capecitabine or pegylated liposomal doxorubicin (PLD).
Charalambous A; Tsitsi T; Astras G; Paikousis L; Filippou E
Eur J Oncol Nurs; 2021 Feb; 50():101866. PubMed ID: 33227569
[TBL] [Abstract][Full Text] [Related]
25. Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials.
Pandy JGP; Franco PIG; Li RK
Support Care Cancer; 2022 Nov; 30(11):8655-8666. PubMed ID: 35655045
[TBL] [Abstract][Full Text] [Related]
26. Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer.
Azuma Y; Hata K; Sai K; Udagawa R; Hirakawa A; Tohkin M; Ryushima Y; Makino Y; Yokote N; Morikawa N; Fujiwara Y; Saito Y; Yamamoto H
Biol Pharm Bull; 2012; 35(5):717-24. PubMed ID: 22687407
[TBL] [Abstract][Full Text] [Related]
27. The effectiveness of EVOSKINĀ®Palm and sole moisturizing cream in treating capecitabine-associated hand-foot syndrome: a randomized double-blind clinical trial.
Lu W; Huang Z; Chen S; Lv H; Chen X; Lei J; Ke C; Hong C; Wei Y; Su R; Chen R; Sun Z; Yang P; Tan X; Liu H
Ann Palliat Med; 2021 Mar; 10(3):3009-3017. PubMed ID: 33849091
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of patient-reported severity of hand-foot syndrome under capecitabine using a Markov modeling approach.
Schmulenson E; Krolop L; Simons S; Ringsdorf S; Ko YD; Jaehde U
Cancer Chemother Pharmacol; 2020 Sep; 86(3):435-444. PubMed ID: 32852627
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of oral administration of cystine and theanine in patients with colorectal cancer undergoing capecitabine-based adjuvant chemotherapy after surgery: study protocol for a multi-institutional, randomised, double-blinded, placebo-controlled, phase II trial.
Hamaguchi R; Tsuchiya T; Miyata G; Sato T; Takahashi K; Ariyoshi K; Oyamada S; Iwase S
BMJ Open; 2018 Jul; 8(7):e021442. PubMed ID: 30030317
[TBL] [Abstract][Full Text] [Related]
30. A randomized phase II study evaluating pyridoxine for the prevention of hand-foot syndrome associated with capecitabine therapy for advanced or metastatic breast cancer.
Toyama T; Yoshimura A; Hayashi T; Kobayashi N; Saito K; Tsuneizumi M; Sawaki M; Hattori M; Nakada T; Yokota I; Iwata H
Breast Cancer; 2018 Nov; 25(6):729-735. PubMed ID: 29948956
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of topical
Mohajerani R; Shahi F; Jafariazar Z; Afshar M
Cutan Ocul Toxicol; 2021 Sep; 40(3):257-262. PubMed ID: 34152880
[TBL] [Abstract][Full Text] [Related]
32. The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study.
Zhang RX; Wu XJ; Lu SX; Pan ZZ; Wan DS; Chen G
J Cancer Res Clin Oncol; 2011 Jun; 137(6):953-7. PubMed ID: 21113620
[TBL] [Abstract][Full Text] [Related]
33. Equivalence study of a topical diclofenac solution (pennsaid) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial.
Tugwell PS; Wells GA; Shainhouse JZ
J Rheumatol; 2004 Oct; 31(10):2002-12. PubMed ID: 15468367
[TBL] [Abstract][Full Text] [Related]
34. Randomized trial of vitamin B6 for preventing hand-foot syndrome from capecitabine chemotherapy.
Braik T; Yim B; Evans AT; Kassem M; Mullane M; Lad T; Hussein L; Cleveland B; McDunn S
J Community Support Oncol; 2014 Feb; 12(2):65-70. PubMed ID: 24971407
[TBL] [Abstract][Full Text] [Related]
35. Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer.
Zielinski C; Lang I; Beslija S; Kahan Z; Inbar MJ; Stemmer SM; Anghel R; Vrbanec D; Messinger D; Brodowicz T
Br J Cancer; 2016 Jan; 114(2):163-70. PubMed ID: 26657657
[TBL] [Abstract][Full Text] [Related]
36. Diclofenac epolamine plus heparin plaster versus diclofenac epolamine plaster in mild to moderate ankle sprain: a randomized, double-blind, parallel-group, placebo-controlled, multicentre, phase III trial.
Costantino C; Kwarecki J; Samokhin AV; Mautone G; Rovati S
Clin Drug Investig; 2011; 31(1):15-26. PubMed ID: 20923251
[TBL] [Abstract][Full Text] [Related]
37. Hemoglobin Value Is the Most Important Factor in the Development of Hand-Foot Syndrome under the Capecitabine Regimen.
Naito M; Yamamoto T; Hara S; Shimamoto C; Miwa Y
Chemotherapy; 2017; 62(1):23-29. PubMed ID: 27229894
[TBL] [Abstract][Full Text] [Related]
38. Diclofenac sodium gel in patients with primary hand osteoarthritis: a randomized, double-blind, placebo-controlled trial.
Altman RD; Dreiser RL; Fisher CL; Chase WF; Dreher DS; Zacher J
J Rheumatol; 2009 Sep; 36(9):1991-9. PubMed ID: 19648310
[TBL] [Abstract][Full Text] [Related]
39. Effect of a Structured Teaching Module Including Intensive Prophylactic Measures on Reducing the Incidence of Capecitabine-Induced Hand-Foot Syndrome: Results of a Prospective Randomized Phase III Study.
Ostwal V; Kapoor A; Mandavkar S; Chavan N; Gupta T; Mirani J; Saklani A; Desouza A; Murugan K; Nashikkar C; Gupta S; Ramaswamy A
Oncologist; 2020 Dec; 25(12):e1886-e1892. PubMed ID: 32717127
[TBL] [Abstract][Full Text] [Related]
40. Proton Pump Inhibitors Ameliorate Capecitabine-induced Hand-Foot Syndrome in Patients With Breast Cancer: A Retrospective Study.
Takemura M; Ikemura K; Yoshinami T; Toyozumi Y; Shintani T; Ueda M; Shimazu K; Okuda M
Anticancer Res; 2022 May; 42(5):2591-2598. PubMed ID: 35489750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
